FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736812323> ?p ?o ?g. }

• W2736812323 endingPage "153" @default.
• W2736812323 startingPage "146" @default.
• W2736812323 abstract "Background Long-term outcomes of adults with first-relapsed/refractory (R/R) systemic anaplastic large-cell lymphoma (ALCL) are not definitively established and should be evaluated. Patients and methods We previously published the long-term outcomes of adults with ALCL initially treated with polychemotherapy in LYmphoma Study Association (LYSA) prospective clinical trials conducted during the pre-brentuximab vedotin era. Herein, we report the long-term outcomes of those patients after the first-relapsed/refractory (R/R) events. Results Among the 138 (64 (anaplastic lymphoma kinase (ALK(+)) and 74 ALK(−) ALCL) adults initially treated in clinical trials, 40 (14 ALK(+) and 26 ALK(−)) first-R/R ALCL patients and their long-term outcomes were analysed. Median follow-up from the first-R/R events was 12.5 years. For ALK(+) and ALK(−) patients, respectively, median [range] findings were as follows: age at first-R/R event: 35 [19–76] and 61 [34–81] years; time between inclusion in first-line clinical trials and first-R/R events was 6 [1.5–34] and 11.1 [1–67] months (P = 0.36); with median (95% confidence interval) progression-free survival after the first-R/R events: 3.8 (0.7–14.8) and 5.3 (2.4–8.4) months (P = 0.39); and overall survival: 13.6 (0.7–89) and 8.1 (3.3–25) months (P = 0.96). ALCL was the main cause of death. Conclusion Most adults with first-R/R ALCL have poor outcomes, with no significant differences between patients with ALK(+) or ALK(−) disease. These results could be used as reference for the evaluation of new drugs to treat R/R ALCL." @default.
• W2736812323 created "2017-07-31" @default.
• W2736812323 creator A5000779514 @default.
• W2736812323 creator A5003078312 @default.
• W2736812323 creator A5012400523 @default.
• W2736812323 creator A5012900514 @default.
• W2736812323 creator A5014942120 @default.
• W2736812323 creator A5017625077 @default.
• W2736812323 creator A5031041032 @default.
• W2736812323 creator A5044625155 @default.
• W2736812323 creator A5052071966 @default.
• W2736812323 creator A5052452447 @default.
• W2736812323 creator A5053019069 @default.
• W2736812323 creator A5075792404 @default.
• W2736812323 creator A5085149424 @default.
• W2736812323 creator A5089493611 @default.
• W2736812323 date "2017-09-01" @default.
• W2736812323 modified "2023-10-16" @default.
• W2736812323 title "Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study" @default.
• W2736812323 cites W1587476434 @default.
• W2736812323 cites W1990487163 @default.
• W2736812323 cites W1993428519 @default.
• W2736812323 cites W2017712465 @default.
• W2736812323 cites W2058767673 @default.
• W2736812323 cites W2074643584 @default.
• W2736812323 cites W2109716912 @default.
• W2736812323 cites W2116068882 @default.
• W2736812323 cites W2116639751 @default.
• W2736812323 cites W2128710193 @default.
• W2736812323 cites W2138023339 @default.
• W2736812323 cites W2139891818 @default.
• W2736812323 cites W2146112074 @default.
• W2736812323 cites W2160516333 @default.
• W2736812323 cites W2168509026 @default.
• W2736812323 cites W2171873783 @default.
• W2736812323 cites W2281041882 @default.
• W2736812323 cites W2310716991 @default.
• W2736812323 cites W2320580975 @default.
• W2736812323 cites W2556504054 @default.
• W2736812323 doi "https://doi.org/10.1016/j.ejca.2017.06.026" @default.
• W2736812323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28735072" @default.
• W2736812323 hasPublicationYear "2017" @default.
• W2736812323 type Work @default.
• W2736812323 sameAs 2736812323 @default.
• W2736812323 citedByCount "19" @default.
• W2736812323 countsByYear W27368123232017 @default.
• W2736812323 countsByYear W27368123232018 @default.
• W2736812323 countsByYear W27368123232019 @default.
• W2736812323 countsByYear W27368123232020 @default.
• W2736812323 countsByYear W27368123232021 @default.
• W2736812323 countsByYear W27368123232022 @default.
• W2736812323 countsByYear W27368123232023 @default.
• W2736812323 crossrefType "journal-article" @default.
• W2736812323 hasAuthorship W2736812323A5000779514 @default.
• W2736812323 hasAuthorship W2736812323A5003078312 @default.
• W2736812323 hasAuthorship W2736812323A5012400523 @default.
• W2736812323 hasAuthorship W2736812323A5012900514 @default.
• W2736812323 hasAuthorship W2736812323A5014942120 @default.
• W2736812323 hasAuthorship W2736812323A5017625077 @default.
• W2736812323 hasAuthorship W2736812323A5031041032 @default.
• W2736812323 hasAuthorship W2736812323A5044625155 @default.
• W2736812323 hasAuthorship W2736812323A5052071966 @default.
• W2736812323 hasAuthorship W2736812323A5052452447 @default.
• W2736812323 hasAuthorship W2736812323A5053019069 @default.
• W2736812323 hasAuthorship W2736812323A5075792404 @default.
• W2736812323 hasAuthorship W2736812323A5085149424 @default.
• W2736812323 hasAuthorship W2736812323A5089493611 @default.
• W2736812323 hasConcept C117643217 @default.
• W2736812323 hasConcept C121332964 @default.
• W2736812323 hasConcept C126322002 @default.
• W2736812323 hasConcept C142424586 @default.
• W2736812323 hasConcept C143998085 @default.
• W2736812323 hasConcept C2776232967 @default.
• W2736812323 hasConcept C2776256026 @default.
• W2736812323 hasConcept C2777872185 @default.
• W2736812323 hasConcept C2778191690 @default.
• W2736812323 hasConcept C2779338263 @default.
• W2736812323 hasConcept C2992779791 @default.
• W2736812323 hasConcept C44249647 @default.
• W2736812323 hasConcept C535046627 @default.
• W2736812323 hasConcept C71924100 @default.
• W2736812323 hasConcept C87355193 @default.
• W2736812323 hasConcept C90924648 @default.
• W2736812323 hasConceptScore W2736812323C117643217 @default.
• W2736812323 hasConceptScore W2736812323C121332964 @default.
• W2736812323 hasConceptScore W2736812323C126322002 @default.
• W2736812323 hasConceptScore W2736812323C142424586 @default.
• W2736812323 hasConceptScore W2736812323C143998085 @default.
• W2736812323 hasConceptScore W2736812323C2776232967 @default.
• W2736812323 hasConceptScore W2736812323C2776256026 @default.
• W2736812323 hasConceptScore W2736812323C2777872185 @default.
• W2736812323 hasConceptScore W2736812323C2778191690 @default.
• W2736812323 hasConceptScore W2736812323C2779338263 @default.
• W2736812323 hasConceptScore W2736812323C2992779791 @default.
• W2736812323 hasConceptScore W2736812323C44249647 @default.
• W2736812323 hasConceptScore W2736812323C535046627 @default.
• W2736812323 hasConceptScore W2736812323C71924100 @default.
• W2736812323 hasConceptScore W2736812323C87355193 @default.

• next